SUMOylation of GSK-3β and upregulation of specific SUMO E3 enzyme of GSK-3β in the tumor microenvironment can inhibit the growth of malignant tumor, which may be used as a potential target for cancer treatment. This evidence concerns the gene GSK3B and neoplasm.